Abstract
Rationale and Objectives Although neuroimaging studies suggest that the cerebral ventricle is independently associated with APOE ε4, cerebrospinal fluid (CSF) biomarkers, and neuropsychological scores in aging and Alzheimer’s disease (AD), there is no formal synthesis of these findings. We summarized the association of ventricular changes with APOE ε4, CSF biomarkers, and neuropsychological measures.
Materials and Methods The Preferred Reporting Items for Systematic reviews and Meta-Analyses guideline was used. PubMed, Scopus, Ovid, Cochrane, and grey literature were searched, and assessment of eligible articles was conducted using the Newcastle-Ottawa Scale.
Results 24 studies met the inclusion criteria. Progressive ventricular volume is increased in AD patients at an average volume of 4.4 – 4.7 cm3/ year compared to average volumes of 2.7 – 2.9 cm3/ year and 1.1 – 1.4 cm3/year for patients with MCI and healthy controls (HCs) respectively. The ventricular volume is estimated to increase by 1.7 cm3/year for progression from MCI to AD. APOE ε4 is an independent risk factor for ventricular enlargement in aging and dementia, with AD patients most affected. The combination of CSF Aβ42 with ventricular volume compared to tau is more robust, for tracking the progression of the AD continuum. Further, the combination of ventricular volume with mini-mental state examination (MMSE) scores is the most robust for differentiating AD and MCI from HCs and tracking the progression of the disease.
Conclusion The combination of ventricular volume with APOE ε4, CSF Aβ42, and MMSE scores independently may be potentially useful biomarkers for differentiating and tracking the progression of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for the present work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a systematic review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All extracted data are included in the manuscript.
